Videos

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor...

Aditi Shastri, MD, discusses the treatment regimen she chose for an older patient with lower-risk, ringed sideroblastic negative myelodysplastic syndrome.

John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.

At the 2024 Pan Pacific Lymphoma Conference, Elaine Jaffe, MD, analyzes the differing classification systems of lymphoma, focusing on diffuse large B-cell lymphoma, follicular lymphoma, and small B-cell neoplasms.

Mark Roschewski, MD, shared expert insight on the possible role of dose-adjusted EPOCH-R as first-line treatment for patients with aggressive B-cell lymphomas.

John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.

Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.